tradingkey.logo


Emergent BioSolutions Inc

EBS
12.430USD
-0.200-1.58%
āļ›āļīāļ” 12/26, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
655.06MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
8.75P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Emergent BioSolutions Inc āļšāļĢāļīāļĐāļąāļ—

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

āļ‚āđ‰āļ­āļĄāļđāļĨ Emergent BioSolutions Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™EBS
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Emergent BioSolutions Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļNov 15, 2006
āļ‹āļĩāļ­āļĩāđ‚āļ­Papa (Joseph C)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™900
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Nov 15
āļ—āļĩāđˆāļ­āļĒāļđāđˆ300 Professional Dr
āđ€āļĄāļ·āļ­āļ‡GAITHERSBURG
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ20879
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ12406313200
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://emergentbiosolutions.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™EBS
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļNov 15, 2006
āļ‹āļĩāļ­āļĩāđ‚āļ­Papa (Joseph C)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Emergent BioSolutions Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
62.55K
-0.97%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Non-U.S Government
83.10M
58.98%
U.S.Government
57.80M
41.02%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 17 āļž.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 17 āļž.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
āļ­āļ·āđˆāļ™ āđ†
72.56%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
āļ­āļ·āđˆāļ™ āđ†
72.56%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
34.85%
Investment Advisor/Hedge Fund
30.34%
Hedge Fund
7.25%
Individual Investor
2.97%
Research Firm
1.58%
Pension Fund
1.08%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.18%
Family Office
0.07%
āļ­āļ·āđˆāļ™ āđ†
20.85%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
378
39.86M
83.14%
+128.30K
2025Q3
417
39.73M
84.87%
+2.04M
2025Q2
439
37.58M
87.40%
+1.14M
2025Q1
454
36.44M
84.55%
-9.64M
2024Q4
461
35.04M
82.31%
+2.84M
2024Q3
467
32.21M
81.37%
+1.29M
2024Q2
485
30.86M
99.60%
-5.54M
2024Q1
494
36.44M
103.37%
-17.72M
2023Q4
512
41.89M
103.68%
-1.06M
2023Q3
563
42.52M
113.85%
-6.21M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
BlackRock Institutional Trust Company, N.A.
3.83M
7.18%
+2.25M
+141.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
6.72%
+370.21K
+11.52%
Jun 30, 2025
State Street Investment Management (US)
1.74M
3.26%
+30.01K
+1.75%
Jun 30, 2025
American Century Investment Management, Inc.
2.29M
4.3%
-5.46K
-0.24%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.85M
3.47%
+252.40K
+15.81%
Jun 30, 2025
Palisade Capital Management, LLC
1.10M
2.06%
-41.83K
-3.66%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.11M
2.07%
+521.91K
+89.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
2.4%
+666.71K
+108.89%
Jun 30, 2025
Acadian Asset Management LLC
974.59K
1.83%
+141.27K
+16.95%
Jun 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
986.67K
1.85%
+55.05K
+5.91%
Jun 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
AdvisorShares Insider Advantage ETF
0.97%
Royce Quant Small-Cap Quality Value ETF
0.41%
State Street SPDR S&P Biotech ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.23%
Harbor Human Capital Factor US Small Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Pacer US Small Cap Cash Cows ETF
0.16%
Invesco RAFI US 1500 Small-Mid ETF
0.15%
Avantis US Small Cap Value ETF
0.14%
iShares Micro-Cap ETF
0.13%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
AdvisorShares Insider Advantage ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.97%
Royce Quant Small-Cap Quality Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.41%
State Street SPDR S&P Biotech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.28%
Federated Hermes MDT Small Cap Core ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.23%
Harbor Human Capital Factor US Small Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.19%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.18%
Pacer US Small Cap Cash Cows ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.16%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.15%
Avantis US Small Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.14%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.13%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Emergent BioSolutions Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Emergent BioSolutions Inc āđ„āļ”āđ‰āđāļāđˆ:
BlackRock Institutional Trust Company, N.A. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 3.83M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 7.18% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
The Vanguard Group, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 3.58M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 6.72% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
State Street Investment Management (US) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.74M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 3.26% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
American Century Investment Management, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 2.29M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 4.30% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Dimensional Fund Advisors, L.P. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.85M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 3.47% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Emergent BioSolutions Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Emergent BioSolutions Inc āđ„āļ”āđ‰āđāļāđˆ
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Emergent BioSolutions Inc (EBS)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 378 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Emergent BioSolutions Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 39.86M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 83.14% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -1.74%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Emergent BioSolutions Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2025Q2 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Commercial Product sales āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Emergent BioSolutions Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 67.50M āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 47.91% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™